Trade Mark Journal No.2021/053 31 December 2021

WO0000001630674 (5)

Office of origin: United States of America

Date of International Registration:18 October 2021
Date of designation in the UK: 18 October 2021
Image for mark 1630674

The mark consists of three curved vertical lines consisting of dots of graduated sizes, with the word "NUGALVIQ" to the right of the design.

International priority date claimed: 13 October 2021 (United States of America) (97072078)
Class 5
Pharmaceutical preparations for treatment of rare orphan diseases; pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; pharmaceutical preparations for inhibiting aldose reductase; pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG).

Applied Therapeutics, Inc.

Representative: Anna Kurian Shaw Hogan Lovells US LLP, 555 13th Street NW, Washington DC 20004, UNITED STATES OF AMERICA